Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

0
Player Avatar neilepi (< 20) Submitted: 1/15/2012 1:15:23 PM : Outperform Start Price: $14.26 DNDN Score: -51.69

Consensus seems positive and looking at the graph there is more white space above than below...

Featured Broker Partners


Advertisement